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Abstract Changes in an individual’s human metabolic
phenotype (metabotype) over time can be indicative of
disorder-related modifications. Studies covering several
months to a few years have shown that metabolic profiles
are often specific for an individual. This ‘‘metabolic indi-
viduality’’ and detected changes may contribute to per-
sonalized approaches in human health care. However, it is
not clear whether such individual metabotypes persist over
longer time periods. Here we investigate the conservation
of metabotypes characterized by 212 different metabolites
of 818 participants from the Cooperative Health Research
in the Region of Augsburg; Germany population, taken
within a 7-year time interval. For replication, we used
paired samples from 83 non-related individuals from the
TwinsUK study. Results indicated that over 40 % of all
study participants could be uniquely identified after 7 years
based on their metabolic profiles alone. Moreover, 95 % of
the study participants showed a high degree of metabotype
conservation ([70 %) whereas the remaining 5 % dis-
played major changes in their metabolic profiles over time.
These latter individuals were likely to have undergone
important biochemical changes between the two time
points. We further show that metabolite conservation was
positively associated with heritability (rank correlation
0.74), although there were some notable exceptions. Our
results suggest that monitoring changes in metabotypes
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over several years can trace changes in health status and
may provide indications for disease onset. Moreover, our
study findings provide a general reference for metabotype
conservation over longer time periods that can be used in
biomarker discovery studies.
Keywords Metabolomics  Longitudinal study 
Heritability  Population study
1 Introduction
The ‘omics’ field has facilitated measuring thousands of
biological entities (e.g., genes, proteins, mRNA transcripts,
and metabolites) with the aim of detecting correlations
between them or their possible association to a disease
phenotype. Metabolomics aims at measuring the concen-
trations of small molecules or metabolites in a given bio-
logical fluid such as plasma, urine, saliva, and breath (Fiehn
2002; Lindon et al. 2006; Martinez-Lozano Sinues et al.
2013; Zhang et al. 2012). Today, with advances in biotech-
nology, modern mass spectrometry has allowed for com-
prehensive measurement of many endogenous metabolites
in a biological fluid. Non-targeted metabolomics approaches
enable the measurement of several hundred to a thousand or
more metabolites from a variety of different metabolic
pathways (Kettunen et al. 2012; Suhre et al. 2011a). Such
technologies facilitate detailed metabolic profiles to an
extent that has not been accessible before. The metabolites
that are measured for each individual characterize the human
metabolic phenotype (or ‘‘metabotype’’), which is defined as
‘‘a probabilistic multi-parametric description of an organism
in a given physiological state based on the analysis of its cell
types, biofluids or tissues’’ (Gavaghan et al. 2000). Human
metabotypes thus represent a comprehensive readout of the
biological state of the human body and have been associated
with a number of human disorders (Amara and Standaert
2013; Fiehn 2002; Halama et al. 2013; Holmes et al. 2008a,
b; Kaddurah-Daouk et al. 2008; Langley et al. 2013; Suhre
et al. 2010, 2011a; Wang et al. 2013).
Metabolomics provides information about the joint
effects of both environmental and lifestyle factors (such as
dietary patterns) and genomics. Changes in the metabolome
can be described by the activity of genes, enzymes, and
proteins that can be associated with conventional or new
target therapies (Corona et al. 2012). This application is
relevant for identifying disease biomarkers from
metabolites, as can be possible in diabetes, obesity, and
cancers (Griffin and Shockcor 2004; Suhre et al. 2010;
Menni et al. 2013) where alterations of metabolite concen-
trations can provide early evidence of disease onset (Assfalg
et al. 2008). Thus, pharmaco-metabolomics, which com-
bines metabolite profiling and chemometrics to model and
predict the efficacy of drug intervention in individuals, has
benefited from this technology (Corona et al. 2012). The field
of nutrigenomics, in which appropriate dietary choices are
sought to avoid metabolic imbalances leading to disease,
presents another motivation for profiling individual metab-
olites (German et al. 2004). However, such fields mainly
depend on the ‘‘individuality’’ or ‘‘uniqueness’’ of human
metabolic profiles because treatment, diet, or drug selection
is specific for each individual based on a specific profile and
one dietary plan can work optimally for an individual but
may predispose others to disease (German et al. 2004).
Although a large day-to-day variability has been shown
in individual metabotypes (Krug et al. 2012; Dallmann
et al. 2012), the metabotype tends to be characteristic of
each person. Both genetic differences and environmental
factors play a role in such ‘‘individuality’’ (Assfalg et al.
2008; Bernini et al. 2009). The variability in an individual
could be due to ‘‘diurnal changes (Walsh et al. 2006),
hormonal status (Bollard et al. 2005), and stage in the
menstrual cycle for women of reproductive age (Wallace
et al. 2010)’’ while differences that characterize individual
metabotypes could be due to factors such as ‘‘gender, age,
and adiposity (Gu et al. 2009; Kochhar et al. 2006; Ras-
mussen et al. 2011; Winnike et al. 2009) or from less well-
characterized habitual dietary patterns and other environ-
mental and cultural influences (Lenz et al. 2003; Holmes
et al. 2008a, b)’’ (Fave et al. 2011). (Heinzmann et al.
2012) indicated that, regardless of dietary patterns, each
individual has a core metabolic fingerprint, influenced by a
combination of many factors such as host metabolism, gut
microbiota composition, dietary habits, physical activity,
and body composition. Several studies have considered this
individuality; for example, (Sampson et al. 2013) studied
within-subject and between-subject variability and identi-
fied metabolites with high within-subject variability that
can be used to distinguish among individuals/metabotypes.
Rather than being only characteristic to each individual at
any given time point, metabotypes should be monitored for
their persistence to a specific individual, or ‘‘conservation’’
over time. Assfalg et al. (2008), and Bernini et al. (2009)
observed clusters of metabotypes of the same individual
taken at different time points, which resulted from higher
variability in inter-individual profiles compared to intra-
individual profiles. Martinez-Lozano Sinues et al. (2013)
observed the persistence of individual signatures over time in
some biofluids, such as breath. However, the time intervals
considered by such studies tend to be relatively short. For
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example, (Saude et al. 2007) studied the variability in human
urine over of a period of 1 month, and (Nicholson et al. 2011)
investigated the stable components in plasma and urine
metabolites over a period of 4 months. In general, studies
have monitored metabolic profiles for short periods, ranging
from a few months and up to 2 or 3 years. However, the
persistence of the individuality of metabotypes over longer
time periods remains unexplored.
Metabolites shape the persistence of metabotype indi-
viduality over time, and identifying the degree of stability of
a metabolite over long periods is thus necessary, in particular
for biomarker discovery studies; biomarker concentration
should not vary too much over the short term within an
individual because such variation would undermine the
predictive association from a single sample (Nicholson et al.
2011). In addition, such markers should not be completely
heritable if environmental factors significantly influence
disease risk. The predictive power of a biomarker has been
speculated to be nested within the metabolite’s longitudi-
nally stable component, yielding an intriguing question
about the stability component of a metabolite versus its
heritability component (Nicholson et al. 2011). However, as
noted, only short periods have been used for such studies, and
the challenge is that (Nicholson et al. 2011) expected a
gradual smooth decay in stable behavior of metabolites with
an increasing time scale from months to years.
We study the conservation of individual metabolic pro-
files or metabotypes over a long term while considering the
effect of metabolite conservation (also referred to as stabil-
ity). Note that we use the term ‘‘longitudinal study’’ in the
narrow sense of a study that considers only two points in time
for every individual. We also address the question of whether
metabolite stability decays over time by studying the con-
servation of metabolites. We further examine the relation of
heritability estimates to metabolite conservation, to under-
stand the metabolome. While previous studies covered time
spans on the order of months or only 2 or 3 years, the present
study is by far the first to expand research into a longitudinal
study of metabotypes/metabolites to time spans of up to
7 years with information on metabolite heritability. Pearson
correlation was used in this study to measure correlation of a
metabolic profile to itself (intra-correlations), as well as
correlations to other profiles (inter-correlations) at the two
time points. Being also done for metabolites, testing the
difference in distributions between intra-correlations and
inter-correlations is an initial step of investigating conser-
vation behavior. A measure derived from these correlations
is the conservation index (see Sect. 2), which we have used to
show that over an interval of 7 years, a large fraction of the
population displays a high degree of metabotype conserva-
tion that correlates with metabotype heritability and that
drastic changes in metabotype occur in only a small fraction
of study participants. These latter differences may be
indicative of important physiological and potentially dis-
ease-related changes.
2 Materials and methods
2.1 Study population
Cooperative Health Research in the Region of Augsburg
(KORA) is an epidemiological research cohort with partic-
ipants randomly selected from the general population in the
region of Augsburg in Southern Germany (Holle et al. 2005).
Here we use samples and data that were collected during the
fourth survey (KORA S4) between 1999 and 2001 and from a
follow-up study (KORA F4) that was conducted 7 years later
between 2006 and 2008. Extensive examinations and phe-
notyping using standardized protocols have been applied and
are described in detail elsewhere (Wichmann et al. 2005 and
references therein). Of 3,080 individuals who attended both
studies, 818 who had metabolite profiles and other covariates
measured at both baseline and follow-up visits were included
in this analysis. These participants were between the ages of
54 and 75 years at baseline with an equal distribution of
males and females. KORA is used here as the discovery
study. For replication, we used data and samples from a
subset of 83 unrelated participants of the TwinsUK cohort.
TwinsUK is a British adult-twin registry with predominantly
female participants. Samples not suitable for this project
from TwinsUK, such as data from a second twin or having a
too short time span between two samplings, were removed.
Study participants were enrolled from the general population
through national media campaigns and were shown to be
comparable to age-matched population singletons in terms of
disease-related and lifestyle characteristics (Andrew et al.
2001). The samples used in this study were derived from
participants ages 30–75 (median 58 years) and are all from
females (because most TwinsUK participants are female).
Multiple samples of TwinsUK participants were collected at
varying time intervals. Here we selected samples that were
collected in variable ranges, with a minimum of 1 year and a
maximum of 13 years apart (mean 8 years; 75 % of the data
points have a range of 6–13 years; histogram is given in
Supplemental Figure 1). For both studies, all participants
gave written informed consent. The studies were approved
by the local ethics committees, the Bayerische Land-
esa¨rztekammer for KORA and Guy’s and St. Thomas’
Hospital Ethics Committee for TwinsUK.
2.2 Blood sampling
Blood for KORA F4 was drawn between 8:00 a.m. and
10:30 a.m. after 10 h fasting. Material was drawn into
serum gel tubes, gently inverted twice, rested for 30 min at
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room temperature to obtain complete coagulation, and then
centrifuged for 10 min at 2,7509g. Serum was divided into
aliquots and kept for a maximum of 6 h at 4 C, after
which it was stored at -80 C until analysis. A similar
blood draw protocol was used in KORA S4 (Rathmann
et al. 2003). For the TwinsUK study, blood samples were
taken after at least 6 h of fasting. The samples were
immediately inverted three times, followed by 40 min of
resting at 4 C to obtain complete coagulation. The sam-
ples were then centrifuged for 10 min at 2,0009g. Serum
was removed from the centrifuged brown-topped tubes as
the top, yellow, translucent layer of liquid. Aliquots were
stored at -45 C until sampling.
2.3 Metabolomics measurements
Metabolic profiling was done on serum using ultrahigh-
performance liquid-phase chromatography and gas-chro-
matography separation, coupled with tandem mass spec-
trometry (UHPLC/MS/MS2 and GC/MS, respectively) at
Metabolon, Inc. (Durham, NC, USA) using established
procedures and technology (Evans et al. 2009; Suhre et al.
2011b). Briefly, Metabolon is a commercial supplier of
metabolic analyses that developed a platform integrating
chemical analysis, including the identification and relative
quantification, data reduction, and quality-assurance com-
ponents of the process. Samples are submitted to three
analyses: to positive- and negative-mode UHPLC/MS/MS2
and to GC/MS. The UHPLC injections were optimized for
basic and acidic species. The resulting MS/MS2 data were
searched against a standard library generated by Metabolon
that included retention time, molecular mass-to-charge
ratio (m/z), and preferred adducts and in-source fragments
as well as their associated MS/MS spectra for all molecules
in the library. The library allowed for the identification of
the experimentally detected molecules on the basis of a
multi-parameter match without the need for additional
analyses. RSD (relative standard deviation) was deter-
mined using repeated measurements of the technical rep-
licates in pooled samples. Supplemental Table 1 gives
details of measurements associated with each metabolite.
Metabolomics measurements for KORA S4, KORA F4,
and TwinsUK were performed in separate batches at Me-
tabolon. Metabolites with more than 20 % missing values
or that were detected only in either the S4 or the F4 sam-
ples were removed, resulting in a dataset of 212 metabolite
levels for 818 participants in KORA and 203 metabolites
for 83 participants in TwinsUK. A total of 135 metabolites
were common to the KORA and the TwinsUK datasets.
Missing data were imputed to the average over all valid
observations of that metabolite at the respective time point.
Metabolite concentrations were z-scored normalized over
all samples.
2.4 Statistical analysis
Analysis was done using the R package (2.15.2). The fol-
lowing definitions are used throughout this paper: For an
individual, the term metabotype is used to refer to the set
(or vector) of metabolite concentrations over the entire set
of metabolites. Time points (t1 or t2) refer to the first and
second data point in each study, i.e., in KORA, t1 refers to
data from the initial S4 survey and t2 to the F4 follow-up.
The term metabotype correlation refers to the Pearson
correlation between the metabolite profiles of two indi-
viduals indi and indj from a cohort C (KORA or TwinsUK)
at two time points, written as r(indi
C(t1), indj
C(t2)). Longi-
tudinal metabotype intra-correlation refers to the correla-
tion of a metabotype of individual i at the first time point to




inter-correlation refers to the correlation of a metabotype
of individual i at the first time point to that of a different
individual j at the second time point and is denoted as
r(indi
C(t1), indj
C(t2)). Metabolite correlation refers to the
Pearson correlation between two metabolite concentration
vectors metk
C(t1) and metl
C(t2) of metabolites k and l at time
points t1 and t2 and is denoted as r(metk
C(t1), metl
C(t2)).
Weighted metabotype correlation refers to the Pearson
correlation between two metabotypes at two time points
using metabolite correlations as weights, calculated using
the following formula:
rw x; yð Þ ¼ covw x; yð Þﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
covw x; xð Þ  covw y; yð Þ
p










where x represents a metabolite concentration vector and
M is the number of metabolites. The weight is calculated as
wk = r(metk
C(t1), metk
C(t2)). The terms weighted longitudi-
nal metabotype inter- and intra correlations are used as for
the normal correlations defined above, but using weighted
correlations.
The conservation index is used for both metabotypes and
metabolites. The metabotype conservation index of an
individual i is defined as the relative rank of the longitudinal
metabotype intra-correlation of that individual with respect
to all longitudinal metabotype inter-correlations of that
individual with all other individuals from the same study
cohort. To calculate this index, the intra-correlations are
converted to ranks to measure a metabotype’s or metabo-
lite’s similarity to itself when compared to its similarity
to other metabotypes or metabolites. It is calculated as
1008 N. A. Yousri et al.
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1 - ((rank(i) - 1)/(N - 1)), where N is number of metab-
otypes. This index quantifies the comparison of intra-corre-
lations to inter-correlations, yielding a value in the range
[0,1]. The metabolite conservation index of a metabolite is
calculated in the same manner as the metabotype conserva-
tion index by replacing vectors of metabotypes with
metabolite concentration vectors. A value of 1 indicates a
fully conserved metabotype or metabolite. For example, in a
3-subjects set (A, B, C) (N = 3), metabotype A has a cor-
relation of 0.5 to itself after 7 years, and a correlation of 0.6
and 0.7 to B and C, respectively, after 7 years. Thus, its
similarity to itself (0.5) is ranked third among all the other
similarities to other metabotypes, and its conservation index
is 0. If B has a correlation of 0.8 to itself and 0.5 to C, then its
self-correlation is ranked first among correlations to others,
meaning that it is fully conserved, thus resulting in a conser-
vation index of 1. The weighted metabotype conservation index
is defined similarly using weighted metabotype correlation.
2.5 Heritability estimates
Heritability estimates (h) were obtained from previous work
based on a large cross-sectional metabolomics dataset from
the TwinsUK study using the Metabolon platform (Shin
et al., submitted manuscript). A total of 212 metabolites
overlapped between the metabolite sets used in that study
and the present work. Briefly, heritability was computed
using monozygotic and dizygotic twin pairs under the ACE
[additive genetic effects (A), shared family environment (C),
and unique environment (E)] model (Zyphur et al. 2013),
which models trait variance as a function of additive genet-
ics, common environment, and unique environment and/or
error effects. The narrow-sense heritability was inferred
from the proportion of the total variance explained by esti-
mated additive genetic effect. Calculations were carried out
using maximum likelihood methods implemented in Open-
Mx software (Boker and Neale 2011) while adjusting for age,
gender, and batch effects.
2.6 Association with age, gender, and BMI
To estimate the impact of age, gender, and BMI, metabolite
levels at KORA S4 were modeled using multi-linear
regression in R, with cofactors gender, age, and BMI [R
code: lm (metabolites * age ? gender ? BMI)]. The 15
most strongly phenotype-associated metabolites were
selected for visualization.
2.7 Principal component analysis (PCA)
R function prcomp was used to obtain the principal
components.
3 Results
3.1 Metabolic profiles of the same individual taken
at time points 7 years apart correlate
Pearson correlation was used to calculate intra- and inter-
correlations between the metabotypes of individuals at two
time points, designated as ‘‘longitudinal’’ intra- and inter-
correlations (see ‘‘Sect. 2’’). These values were calculated
based on 818 individual metabotypes using 212 metabolites
studied at the two time points S4 and F4 for the KORA cohort.
The distributions of the pairwise longitudinal inter- and intra-
correlations for KORA are shown in Fig. 1a. The median of
the longitudinal intra-correlations was 0.35 and significantly
different from zero (p \ 2.2 9 10-16), but there was no
observable correlation among the metabotypes of different
individuals (longitudinal metabotype inter-correlation med-
ian = -0.0012). This observation was replicated in the
TwinsUK study based on 83 unrelated female study partici-
pants and 203 metabolites taken at two time points that were
on average 8 years apart. The median for the longitudinal
metabotype intra-correlation was 0.26; for the inter-correla-
tions, it was -0.0042 (Supplemental Figure 2a).
3.2 Unique identification of 40 % of KORA study
participants based on their metabolic profiles is
possible after 7 years
As a measure of human metabolic profile persistence over
time, the metabotype conservation index was used. This index
measures the relative rank of the individual metabotype’s
longitudinal intra-correlation (correlation to self over time)
within its longitudinal inter-correlation values (correlations to
others over time). A conservation index value of 1 was
observed for 334 out of the 818 KORA study participants,
indicating that 40 % of the study participants could be
uniquely identified after 7 years based on information about
their metabolic profiles alone. Moreover, 95 % of the me-
tabotypes had a conservation index above 0.7; i.e., the corre-
lation of a metabotype in S4 to itself in F4 was ranked among
the 30 % highest correlations with all other metabotypes in
F4. Conversely, only 5 % of the individuals showed low
conservation over time; i.e., they drastically changed their
metabolic profiles over the 7-year period (black curve in
Fig. 2a). This observation was also replicated in the TwinsUK
study: 37 % of the participants showed a metabotype con-
servation index value of 1, and 95 % of all metabotypes had a
conservation index above 0.57 (black curve in Fig. 2b).
3.3 Metabolic traits are also conserved over time
We computed metabolite conservation indices and Pearson
correlations for each metabolite (using correlations
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between individual metabolite concentrations from all
individuals) for both KORA (212 metabolites) and Twin-
sUK (203 metabolites) (Supplemental Figure 3). Medians
of metabolite longitudinal intra-correlations were 0.322
and 0.28 for KORA and TwinsUK, respectively. For 135
metabolites that were observed in both studies, we com-
pared the metabolite conservation between the KORA and
the TwinsUK studies and observed a high rank correlation
(r = 0.69, p \ 2.2 9 10-16) between the Pearson
correlations of the metabolites from both sets. For KORA
the 10 most strongly conserved metabolites are shown at
the top of Table 1 and comprise 6 out of 10 sterols and
steroids. With regard to other metabolite classes, lysolipids
appeared among the 25 % least-conserved metabolites, and
10 out of 16 long-chain fatty acids belonged to the 50 %
least-conserved metabolites. Nine out of twelve metabo-
lites associated with valine, leucine, and isoleucine
metabolism were in the top 25 % of the most-conserved
Fig. 1 Metabotype pairwise longitudinal inter correlations versus
intra correlations distributions between KORA S4 and F4. a Pearson
correlation of the metabolite levels between two time points for the
same individual, or intra-correlations [median is 0.35 (red histogram)]
and for pairwise inter correlations [median is -0.0012 (blue
histogram)]. b As in a, but using metabolite correlations as weights
to metabotype correlations [medians are 0.58 for intra-correlations
(red) and -0.0018 for pairwise inter-correlations (blue)]
Fig. 2 Metabotype conservation index. The conservation index of the
metabotype of a study participant is defined as the relative rank of the
longitudinal intra correlation of the metabolic profile of that
individual compared to the longitudinal inter-correlations with the
profiles of all other study participants. The conservation index is
plotted in black, while using weighting with metabolite correlations is
shown in red; In KORA (a), 40 % of the subjects have a metabotype
conservation index of one, which increases to 52 % when metabolite-
weighting is used. In the TwinsUK replication (b), the corresponding
conservation index values are 37 % (black curve) and 61 % (red
curve), for unweighted and weighted conservation index respectively
1010 N. A. Yousri et al.
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Table 1 Selected metabolites with conservation [as longitudinal
intra-correlations (r)] and heritability estimates (h), restricted to
metabolites with conservation or heritability greater than 0.45, which
is the union of two regions of heritability ranks bounded by a ceiling
of 28 and conservation ranks bounded by a ceiling of 46; ranks and
difference in ranks between conservation and heritability for each
metabolite are given, significant association (p \ 0.05 after Bonfer-
roni correction for 212 tests) of metabolites with age, gender and BMI
as to a linear model (see ‘‘Sect. 2’’) are indicated by ‘x’
Metabolite r Rank (r) h Rank (h) |Rank (h) – Rank (r)| Sex Age BMI
4-Androsten-3beta,17beta-diol disulfate 1 0.795 1 0.604 10 9 x x
Dehydroisoandrosterone sulfate 0.777 2 0.607 8 6 x x
4-Androsten-3beta,17beta-diol disulfate 2 0.769 3 0.582 13 10 x x
5Alpha-androstan-3beta,17beta-diol disulfate 0.750 4 0.592 12 8 x
Pyroglutamine 0.739 5 0.595 11 6 x
Butyrylcarnitine 0.720 6 0.764 2 4 x x
Thromboxane B2 0.702 7 0.606 9 2 x x
Androsterone sulfate 0.697 8 0.712 3 5 x
Creatine 0.690 9 0.573 14 5 x x
Epiandrosterone sulfate 0.683 10 0.650 4 6 x
Alpha-hydroxyisovalerate 0.642 11 0.557 15 4 x x
3-(4-Hydroxyphenyl)lactate 0.640 12 0.420 37 25 x x
proline 0.610 13 0.542 17 4 x
1,5-Anhydroglucitol 0.595 14 0.609 6 8 x
3-Dehydrocarnitine 0.590 15 0.516 18 3 x
Urate 0.587 16 0.609 7 9 x x
N-Acetylornithine 0.551 17 0.553 16 1
Glycine 0.546 18 0.465 24 6 x x
Isoleucine 0.544 19 0.486 20 1 x x
3-Carboxy-4-methyl-5-propyl-2-furanpropanoate 0.528 20 0.365 54 34
Glutaroylcarnitine 0.523 21 0.620 5 16 x
Isobutyrylcarnitine 0.522 22 0.464 26 4
3-Methyl-2-oxovalerate 0.508 23 0.225 137 114 x x
Gamma-glutamylleucine 0.505 24 0.348 59 35 x x
Leucine 0.499 25 0.433 34 9 x x
Betaine 0.498 26 0.417 40 14 x
4-Vinylphenol sulfate 0.497 27 0.334 67 40 x x
2-Methylbutyroylcarnitine 0.491 28 0.318 77 49 x x
Octanoylcarnitine 0.489 29 0.474 21 8
Isovalerylcarnitine 0.486 30 0.472 22 8 x x
C-Glycosyltryptophan 0.481 31 0.465 25 6 x
Hexanoylcarnitine 0.474 32 0.492 19 13
Kynurenine 0.473 33 0.433 33 0 x x
4-Methyl-2-oxopentanoate 0.472 34 0.139 175 141 x
Serotonin 0.468 35 0.331 69 34 x
Valine 0.468 36 0.412 43 7 x x
Cis-4-decenoyl carnitine 0.464 37 0.436 32 5
Erythronate 0.463 38 0.311 81 43 x
2-Hydroxybutyrate 0.463 39 0.346 60 21 x x
p-Cresol sulfate 0.463 40 0.367 51 11
Gamma-glutamylvaline 0.459 41 0.244 125 84 x x
Phenylacetylglutamine 0.458 42 0.332 68 26
7-Alpha-hydroxy-3-oxo-4-cholestenoate 0.456 43 0.298 92 49 x x
Decanoylcarnitine 0.455 44 0.416 41 3
Docosahexaenoate 0.453 45 0.322 74 29
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metabolites. Carbohydrates were more divided, with some
showing higher (e.g., 1.5 anhydroglucitol) and others lower
conservation over time (e.g., pyruvate).
3.4 Weighting metabotype correlation using metabolite
conservation increases the uniquely identifiable
fraction in KORA to 52 %
We hypothesized that metabolites that show a higher
conservation over time also carry more information
regarding an individual’s metabotype. Figure 1b shows the
distributions of weighted longitudinal intra- and inter-cor-
relations between the metabotypes of KORA at S4 and F4,
where weights are the longitudinal intra-correlations of
metabolites (replication for the TwinsUK set is presented
in Supplemental Figure 2b). The weighting increased the
median of the metabotype intra-correlations from 0.35 to
0.58 for the KORA set and from 0.26 to 0.53 for the
TwinsUK set. Extending this weighting scheme to the
conservation index (see Sect. 2), we observed a 30 %
increase in the number of individuals who could be
uniquely identified based on their metabolite profiles (from
40 % to 52 %; red curve in Fig. 2a). On an individual
basis, 43 % of the participants showed an increased con-
servation index while only 22 % had a decreased index
under this weighting procedure. For 95 % of the individ-
uals, the metabotype conservation index was larger than
0.83, compared to 0.7 without weighting. In the TwinsUK
replication study, the fraction of uniquely identifiable
individuals increased from 37 to 64 % after weighting,
with 95 % of all individuals having a conservation value
over 0.78 (red curve in Fig. 2b).
3.5 Individuals who display a strong change in their
metabotype over time are not different
from the general population
About 5 % of all individuals showed low longitudinal
metabotype conservation (Fig. 2). To investigate whether
these individuals represented outliers with extreme me-
tabotypes, we conducted PCA. Figure 3 shows the first two
dimensions of the PCA for the KORA S4 and F4 datasets,
Table 1 continued
Metabolite r Rank (r) h Rank (h) |Rank (h) – Rank (r)| Sex Age BMI
Citrate 0.451 46 0.386 49 3 x
Citrulline 0.444 47 0.471 23 24 x
Succinylcarnitine 0.418 58 0.450 28 30 x
Carnitine 0.380 73 0.453 27 46
Homostachydrine 0.315 109 0.868 1 108 x
The complete dataset with p values and beta-estimates is available as Supplemental Table 1
Fig. 3 PCA of KORA S4 (a) and F4 (b) shows the 5 % least
conserved individual metabotypes (red dots) after weighting metab-
otype conservation index using metabolite correlations. The least
conserved metabotypes do not show a different behavior than the rest
of the data, thus using both time points S4 and F4 with the
conservation index is the method for identifying those least conserved
ones
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respectively. The 5 % of the least-conserved metabotypes
were within the data distribution of all other individuals
and thus not different from the normal population (Fig. 3).
3.6 Most highly conserved metabolites are also highly
heritable
We expected conservation of individual metabotypes to be
influenced by genetic factors and hence partially heritable.
To compare metabolite conservation to metabolite herita-
bility, heritability estimates were obtained from an inde-
pendent TwinsUK heritability study of over 6,000 twins
(Shin et al., submitted). Figure 4 shows a cross-plot of
heritability ranks and conservation ranks for all metabo-
lites. The rank correlation between heritability and con-
servation was 0.74 (p \ 2.2 9 10-16). Table 1 presents
metabolite heritability estimates, correlation values, and
respective ranks for a selected set of metabolites (full
dataset, Supplemental Table 1).
3.7 Gender, age, and BMI are associated
with metabolite heritability and conservation
Gender is a conserved phenotype while BMI might change
slightly over time. On the other hand, age increases iden-
tically for all individuals. Metabolites that are biomarkers
for these phenotypes should thus display a higher-than-
average conservation over time. To identify metabolites
strongly associated with these phenotypes in the present
study, linear regressions of metabolite concentrations to
gender, age, and BMI were calculated (using data from the
KORA S4 dataset). For each phenotype, metabolites
significantly regressing (p \ 0.05/212) and non-signifi-
cantly regressing were compared for their heritability and
conservation ranks, using the Wilcoxon rank test. Metab-
olites significantly associating with gender were also more
significantly associated with high conservation ranks
(p = 4.7 9 10-9) and with high heritability ranks (p =
7.1 9 10-5). Age-related metabolites also correlated with
high conservation (p = 6.9 9 10-4) and with high herita-
bility (p = 3.8 9 10-4), as did BMI (p = 4.6 9 10-6 and
2.4 9 10-3, for high conservation and high heritability,
respectively). The 15 metabolites that associated most
strongly with each phenotype are highlighted in Fig. 4b
and Supplemental Table 2.
4 Discussion
4.1 Metabotype conservation
Metabolite Pearson correlations (intra-correlations between
two time points) were used in this analysis to calculate a
weighted metabotype conservation index as described in
Sect. 2. Weighting of the metabotype correlations with the
conservation of the individual metabolites over time was
motivated by the observation that not all metabolites may
be equally informative to identify individuals with drastic
changes in their metabotype over time. For instance, vari-
ability can result from a stronger dependency on varying
lifestyle factors (e.g., metabolites from diet) but also from
lower measurement quality (higher RSD; see Fig. 4a). The
impact of metabolite conservation on the metabotype
conservation index (i.e., the 30 % increase in metabotypes
Fig. 4 Heritability of metabolic traits compared to their conservation
between two time points. a Marker size is proportional to the variance
of technical replicates compared to their mean (RSD), and showing
more heritable than conserved region in the blue ellipse area, and
more conserved than heritable region in the red ellipse area. b The 15
most strongly associated metabolites with gender (red), age (blue),
and BMI (green) (see Supplemental Table 2 for metabolite names)
Long term conservation 1013
123
with a conservation index of 1 after weighting with
metabolite longitudinal intra-correlations) shows that
highly conserved metabolites can be used to better distin-
guish individuals. This result is also supported by the
findings of (Sampson et al. 2013) because some of the
highly conserved metabolites from our study (Table 1)
have also shown high inter-subject variability, i.e., proving
to be better at discriminating individuals (see Supplemental
Table 3).
Metabotypes can be divided into three categories:
strictly conserved metabotypes, or those with a conserva-
tion index value of 1 (52 % of the population); highly
conserved metabotypes, or those with a conservation index
value in the interval [0.83,1] (43 % of the population); and
least-conserved metabotypes, or those with a value in the
interval [0,0.83] (5 % of the population). However, the 5 %
least-conserved metabotypes presented an intriguing
question regarding whether they are entirely different from
the ‘‘normal’’ population.
To address this question, we applied PCA to KORA S4
and F4 samples to determine whether the 5 % least-con-
served metabotypes are separated from the remaining me-
tabotypes. When projected onto the first two principal
components (Fig. 3), the PCA did not distinguish the least-
conserved metabotypes as outliers relative to the remaining
population. Other explorative techniques (such as hierar-
chical clustering) were used to determine if the 5 % me-
tabotypes could be distinguished as having extreme
behavior from the 95 % metabotypes when exploring each
of S4 and F4 separately, as well as exploring the PCA of
the mean metabotype behavior (calculated as the average
of the S4 and F4 metabolic profiles for each metabotype).
The results showed that no extreme behavior of the me-
tabotypes could be determined using these techniques,
either (data not shown). Thus, the two time points together
rather than one time point (i.e., the longitudinal study using
the conservation index) can be used to distinguish such
highly changing metabotypes, once again highlighting the
importance of long-term studies in detecting the abnormal
behavior of metabotypes. Whether such individuals have
experienced important changes in their lifestyles or
developed severe diseases requires additional investigation.
Results from metabotype conservation analysis further
motivate the study of factors affecting metabolite behavior
over time, whether because of lifestyle, environment, or
genetics.
4.2 Metabolite conservation analysis
The conservation analysis addressed the question posed by
Nicholson et al. (2011) regarding the decay of metabolite
stability over time. Our results indicate that even after
7 years, some metabolites remain highly conserved and
contribute to increasing metabotype conservation. In
exploring the conservation behavior of metabolites in dif-
ferent pathways, we found that the 6 steroids in the top 10
most-conserved metabolites are mostly in the androsterone
pathway, which is explained by the discriminative power of
gender as a ‘‘natural’’ individual classifier. Results from
regression with gender, age, and BMI and the Wilcoxon
test indicate that gender-related metabolites are more sig-
nificantly associated with high conservation compared to
age- and BMI-related metabolites. The conservation of
gender-related metabolites has its role in increasing the
metabotype conservation index, as indicated previously.
This finding suggests their usability in studying the
uniqueness of individual metabotypes over the long term.
On the lower end of the conservation spectrum are lysoli-
pids and the majority of the long-chain fatty acids; lysoli-
pids are affected by nutrition but are also associated with
high RSD values ([25; see Supplemental Table 1),
implying that further investigation is needed for these
metabolites. Examples of long-chain fatty acids that are not
highly conserved include palmitate, oleate, and stearate,
which are fatty acids that occur naturally in various animal
and vegetable fats and oils (HMDB: http://www.hmdb.ca),
and eicosenoate, which is found in a variety of plant oils.
Another is margarate (heptadecanoic acid), which is known
as a biological marker of long-term milk fat intake in
populations with a high consumption of dairy. Food intake
and lifestyle thus highly affect these long-chain fatty acids.
Among the more conserved carbohydrates are 1,5-anhy-
droglucitol (1,5-AG), mannose, glucose, lactate, and ery-
thronate. Because 1,5-AG is a known biomarker for short-
term glycemic control (Buse et al. 2003), it is thus expected
to be stable over time. It also shows a higher stability than
glucose, which makes it even a stronger biomarker for
diabetes. Urate appears in the top-conserved metabolites
and is known to be a biomarker for Parkinson’s disease
(Cipriani et al. 2010). With this overview, we have pro-
vided an example of using these results to identify
metabolites that can be potentially used as biomarkers
because of their stability.
Carbohydrates falling in the low-conserved region are
pyruvate, erythrose, glycerate, and fructose, likely because
of their high technical variance with RSD values above 25.
Pyruvate showed a very low conservation compared to the
more highly conserved glucose and lactate, which are in
the same glycolysis pathway, and thus the RSD might
explain this contradiction (Supplemental Table 1 shows
annotation with pathways and superpathways together with
correlation and heritability ranks of metabolites). This
finding also suggests that low-conserved metabolites
should be avoided when studying a metabolic disorder over
time because their change with time arises from their
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instability rather than from an effect of the disorder’s
metabolic influence.
To detect whether the conservation of some metabolites
is affected by a higher conservation in one sex than the
other, males and females were separated and the intra-
correlations of metabolites calculated for both sexes sepa-
rately, but we found no significant variation between the
values obtained for each sex (Supplemental Figure 4).
4.3 Heritability versus conservation study
Deviation between heritability ranks and conservation
ranks can be used to identify metabolites that may be
conserved as a result of dietary patterns or lifestyle from
those that are more conserved because of their genotype
association. We ordered metabolites in a descending order
based on the absolute difference in heritability and con-
servation ranks. With this approach, taking 100 as the
lower bound of absolute difference, two groups of metab-
olites are at the top. The first group consists of metabolites
that are more conserved than heritable (they appear below
the diagonal, and more towards the lower right corner of
heritability graph in Fig. 4), which includes 4-methyl-2-
oxopentanoate, 3-methyl-2-oxobutyrate, 3-methyl-2-ox-
ovalerate from valine, leucine, and isoleucine metabolism,
methyl palmitate from fatty acid metabolism, and glucose
and lactate from the glycolysis pathway. The second group
consists of metabolites that are more heritable than con-
served (they appear above the diagonal and towards the
upper left corner of heritability graph in Fig. 4), and these
include theobromine, glycerate, and homostachydrine.
Supplemental Table 2 highlights the significance of asso-
ciation of some of these metabolites with gender, age, and
BMI. Glucose and lactate are examples of metabolites that
are only moderately conserved (with conservation ranks of
59 and 60 and heritability ranks of 161 and 169, respec-
tively), in contrast to 1,5-anhydroglucitol, which shows a
high heritability and a high conservation, and pyruvate,
which shows least heritability and conservation. From the
second group of metabolites, those that are more heritable
than conserved, glycerate significantly regressed with
gender, and homostachydrine significantly regressed with
age. Homostachydrine is a food compound found in citrus
fruits, and citrus fruit intake undergoes both seasonal and
daily variations in Germany. Because the KORA surveys
were conducted over periods that are longer than 1 year
and participants were enrolled randomly with respect to
season, low correlation between the availability of citrus
fruits to individual participants between S4 and F4 is to be
expected, which may explain the lack of conservation of
homostachydrine levels between S4 and F4 despite its high
heritability.
Other groups of metabolites show high heritability and
high conservation or low heritability and low conservation.
The first group of metabolites appears in Table 1 and is
significantly associated with gender, as also confirmed with
results of regression to gender, age, and BMI. The other
group is near the lysolipids region (upper right corner of
heritability graph in Fig. 4a) and where metabolites are
also associated with high RSD values (Fig. 4a). Pathway
and subpathway annotation of metabolites on the herita-
bility graph is given in Supplemental Table 1.
Results from associating heritability with conservation
reveal variability among metabolites and relate it to the
biological background. Along with the results of the effect
of conservation on distinguishing metabotypes, these
findings can be used to distinguish disorder-related phe-
notypes and characterize them as arising from heritability
or lifestyle. Disorder-related metabolites can also be used
in prediction of abnormalities in longitudinal studies.
4.4 Limitations of the present study
Although the conservation of metabotypes confirms earlier
findings from comparatively short-term studies and
metabolite conservation shows results consistent with sta-
ble phenotypes (such as gender), several limitations of this
study should be kept in mind. Some variation may have
resulted from laboratory/technical errors associated with
sample storage and the variation in the time of day at which
the samples were collected at each time point. Other
influences that might be limiting include the stability of
serum between extraction and metabolomics analysis and
variations attributable to the fasting behavior of the
participants.
We use simple Pearson correlation between time points,
neglecting possible influences of age, gender, and BMI on
the correlation values of metabolites. However, a linear
regression model that corrects for those factors was also
used to calculate the correlation of metabolites and the
resulting conservation index in order to evaluate the effect
of these covariates. Using this more complex model did not
substantially change our main results, as presented in
Supplemental Figure 5.
The TwinsUK cohort presented varying time differences
among participants (see Supplemental Figure 1) on the
metabotype conservation. We therefore only used it for
replication. It would have been interesting to study the
impact of the time difference on metabolite and metabo-
type conservation. However, KORA involved only a fixed
time difference between the two time points (i.e., 7 years),
while the number of participants in the TwinsUK cohort
was too low to expect statistically significant results from
such an analysis, which thus was not done.
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5 Conclusion
We studied the long-term conservation of human individual
metabolic profiles over 7 years, an essential step for
extrapolation from short-term studies. We also analyzed
metabolite conservation and identified poorly and highly
conserved examples. More than half of the study participants
could be uniquely identified after 7 years for both the KORA
and TwinsUK cohorts, based on their metabotype conser-
vation index. Highly conserved metabolites increased this
uniqueness. Heritability and the 7-year conservation of
metabolites were highly correlated, and the two measures
together revealed variations in metabolite behavior.
Metabolites that showed extremely high conservation
compared to heritability or vice versa were explored for
biological relevance. Results confirm the long-term con-
servation of individuality of metabotypes, further increasing
the possibility of using metabolomics as a surrogate for
understanding the systems biology underlying normal and
diseased phenotypes. Metabolites reported here may be
investigated as potential long-term biomarkers to detect
normality/abnormality of changes in human metabolic
profiles. They also stand as a reference when studying long-
term changes in a metabolic disorder and to identify whether
changes are the result of metabolite or disorder instability
over time. The characterization of metabolites based on
heritability and conservation will also be useful in under-
standing disease pathways and interpreting clinical studies.
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